MONTREAL, QUEBEC--(MARKET WIRE)--Aug 29, 2007 -- Mistral Pharma Inc. (CDNX:MIP.V - News) (the "Corporation", "Mistral") announces today its financial results and review of operating highlights for the first quarter ended June 30, 2007. "The highlights of Mistral's first quarter were the successful acquisition of CuraMedica (Canada) Inc. ("CuraMedica") and the approval of Instillagel(®) by Health Canada", said Bertrand Bolduc, the Corporation's President & CEO. "We are working closely with our partners to realize a successful product launch in the fall of 2007" he added.
